Second Consecutive Year Of Growth In NME Approvals In The Cards For FDA
Executive Summary
It looks to be a good bet that 2009 will mark a second year of growth in new drug approvals: FDA entered the second half of the year with a robust first-half NME approval tally and a well-stocked pipeline of novel agents with user fee goal dates in the remaining months of the year
You may also be interested in...
The REMS Ramp Up: FDA Using New Safety Tools More Frequently In Year Two
FDA is using its new Risk Evaluation and Mitigation Strategy authorities much more frequently in the second year since the law took effect
The REMS Ramp Up: FDA Using New Safety Tools More Frequently In Year Two
FDA is using its new Risk Evaluation and Mitigation Strategy authorities much more frequently in the second year since the law took effect
Chart: Biologicals Approved In 2009
Biologicals Approved In 2009